SCOLR Pharma, Inc. Reports Third Quarter 2008 Financi... ( The Company also completed its previo...)

SCOLR Pharma, Inc. Reports Third Quarter 2008 Financial Results

Date:11/7/2008

The Company also completed its previously announced lease termination and buyout transaction under which we received $4.1 million and successfully relocated its corporate headquarters to a more cost effective and better equipped facility."

Mr. Wilds concluded, "We are very encouraged by our achievement of important business and clinical milestones during the past quarter. By continuing to focus on partnering our lead product candidates, limiting additional drug development initiatives to those already partnered and in active collaborations, we expect that the net proceeds from the lease buyout and our current financial resources together with continuing expense management should be sufficient to fund our operations through 2009."

Total revenues, which consist of royalty revenue from our collaboration agreements, increased 14%, or $28,834 to $236,308 for the three months ended September 30, 2008, compared to $207,474 for the same period in 2007. This increase is primarily due to higher royalty income from our relationship with Perrigo.

Total revenues decreased 55% or $968,013 to $781,435 for the nine months ended September 30, 2008, compared to $1.7 million for the same period in 2007. The higher total revenues for 2007 were primarily due to approximately $621,222 of research and development fees and licensing revenues from an agreement terminated in the first quarter of 2007.

Net income for the three months ended September 30, 2008, was $890,370 compared to a net loss of ($3.1) million for the same period in 2007. Net loss for the nine months ended September 30, 2008, decreased 55%, or $3.9 million to $3.2 million, compared with a net loss of $7.1 million for the same period in 2007. The decrease in the net loss was primarily due to the $4.0 million net gain from the termination of the lease on our corporate facility.

In May 2008, we entered into an agreement to terminate the lease of our corporate facility for $4.1 million. Un
'/>"/>

SOURCE SCOLR Pharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8
Related medicine technology :

1. SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen
2. FluoroPharma, Inc. to Report Preclinical Data on Alzheimers Disease and Prostate Cancer PET Imaging Agents
3. CB1400, Patented by Canopus BioPharma, Enters Phase II Clinical Trials for the Prevention of Mucositis in Patients With Cancer of the Head and Neck
4. Victory Pharma, Inc. Reports MGX006 Enters Into Pivotal Development Program
5. Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update
6. Bavarian Nordic Reports Successful Safety Data From Phase II Study With IMVAMUNE(R)
7. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/IDSA Joint Meeting
8. Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
9. Novexel Reports Positive Phase II Trial Results With NXL103 in Adult Patients With Community Acquired Pneumonia
10. Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio
11. Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting

Post Your Comments:

(Date:12/14/2009)... -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT ) ... of Allowance from the United States Patent and ... application no. 11/060,641, which covers the composition and ... tablet), the lead Transcept product candidate. Once ... February 2025. ,, "This is the second USPTO ...

(Date:12/14/2009)... Dec. 14 Embarrassing and sometimes uncomfortable colonoscopies ... National researchers are taking note of a new screening ... process. The Knoxville-based company, EDP Biotech Corporation ... ColoMarker, an affordable medical device doctors can use to ... "When you consider that 30% of colon cancer ...

(Date:12/14/2009)... Dec. 14 Following is a statement ... Consumer Healthcare Products Association (CHPA), regarding today,s release ... Monitoring the Future survey: ,, "Findings released today ... to the need for continued efforts to educate ... to talk to their teens about medicine abuse. ...

Breaking Medicine Technology:Transcept Pharmaceuticals Receives Notice of Allowance for Second U.S. Patent Application Covering Intermezzo(R) 2 Transcept Pharmaceuticals Receives Notice of Allowance for Second U.S. Patent Application Covering Intermezzo(R) 3 Transcept Pharmaceuticals Receives Notice of Allowance for Second U.S. Patent Application Covering Intermezzo(R) 4 EDP Biotech Takes Next Step in the Development of ColoMarker 2 EDP Biotech Takes Next Step in the Development of ColoMarker 3 Statement From the Consumer Healthcare Products Association(CHPA) on Annual Monitoring the Future Survey on Drug Abuse 2 Statement From the Consumer Healthcare Products Association(CHPA) on Annual Monitoring the Future Survey on Drug Abuse 3 Provider of Diabetes Medical Supplies Receives 2009 Best of Boca Raton Award 55669 1 Provider of Diabetes Medical Supplies Receives 2009 Best of Boca Raton Award 55669 2 Abbott Launches Next Generation XIENCE PRIME 28TM 29 Drug Eluting Stent in International Markets 55665 1 Abbott Launches Next Generation XIENCE PRIME 28TM 29 Drug Eluting Stent in International Markets 55665 2 Abbott Launches Next Generation XIENCE PRIME 28TM 29 Drug Eluting Stent in International Markets 55665 3 Abbott Launches Next Generation XIENCE PRIME 28TM 29 Drug Eluting Stent in International Markets 55665 4 Abbott Launches Next Generation XIENCE PRIME 28TM 29 Drug Eluting Stent in International Markets 55665 5 Boston Scientific Names Leading Electrophysiologist to Its Medical Team 55662 1 Boston Scientific Names Leading Electrophysiologist to Its Medical Team 55662 2 Boston Scientific Names Leading Electrophysiologist to Its Medical Team 55662 3

[0] Transcept Pharmaceuticals Receives Notice of Allowance for Second U.S. Patent Application Covering Intermezzo(R)[0] EDP Biotech Takes Next Step in the Development of ColoMarker [0] Statement From the Consumer Healthcare Products Association(CHPA) on Annual Monitoring the Future Survey on Drug Abuse

... Clinical Experience with Antimicrobials that are Biological Basis ... Pharmaceuticals, Inc. (NYSE Amex: NBY ), ... products to treat and prevent a wide range ... resistance, today announced an exclusive agreement with Professors ...

... 21 Scientists from the Barbara Ann Karmanos ... the American Association for Cancer Research,s 100th Annual ... future for children who suffer from a more ... Ge, Ph.D., and Chengzhi Xie, Ph.D., presented a ...

Other Medicine Technology:NovaBay(R) Pharmaceuticals Enters into Agreement to Broaden Intellectual Property Estate and Expand Clinical Opportunities for Its Aganocide(R) Compounds 2 NovaBay(R) Pharmaceuticals Enters into Agreement to Broaden Intellectual Property Estate and Expand Clinical Opportunities for Its Aganocide(R) Compounds 3 NovaBay(R) Pharmaceuticals Enters into Agreement to Broaden Intellectual Property Estate and Expand Clinical Opportunities for Its Aganocide(R) Compounds 4 Karmanos Cancer Institute Researchers Study New Drug Combinations to Treat Childhood Leukemia 2 Karmanos Cancer Institute Researchers Study New Drug Combinations to Treat Childhood Leukemia 3

NovaBay(R) Pharmaceuticals Enters into Agreement to Broaden Intellectual Property Estate and Expand Clinical Opportunities for Its Aganocide(R) Compounds Karmanos Cancer Institute Researchers Study New Drug Combinations to Treat Childhood Leukemia

(Date:12/15/2009)... employment opportunity for the unemployed or those needing additional income... known ... today. , ... Orlando, FL (PRWEB) December 15, 2009 ... is spreading holiday cheer and good will that is going to ... an opportunity for out of work Americans to get back to ...

(Date:12/15/2009)... Accelify is proud to announce the addition ... David will serve as Director of Development in the ... Board of Advisors. ,, David Tokofsky was ... of Education in June 1995. As the Board Member ... 600,000 stretching from Northeast Los Angeles through East Los ...

(Date:12/15/2009)... Reportlinker.com announces that a ... in its catalogue: ,, The ... Market Forecasts to 2015, Competitive Benchmarking, ... ,, http://www.reportlinker.com/p0168098/The-Future-of-Cardiovascular-Diseases-Therapeutics---Market-Forecasts-to-2015-Competitive-Benchmarking-Product-Pipeline-and-Deals-Analysis.html ,, ... released its latest research "The Future ...

(Date:12/15/2009)... Dec. 15 Hospira, Inc. (NYSE: ... in generic injectable pharmaceuticals, and Orchid Chemicals ... a leading Indian pharmaceuticals company and among ... today announced an agreement for Hospira to ... business for approximately $400 million. ,, ...

(Date:12/15/2009)... generally associated with different tests and/or prescriptions for ... doctors and midwives are agreed that gynaecological visits ... reveals a thesis from the Sahlgrenska Academy at ... women see sex as a problem, the thesis ... about their sex lives, their relationships and how ...

[0] RPS Worldwide Launches Affiliate Program -- The Collection Agency That Gives Christmas Back, Rather Than Take it Away [0] Accelify Announces the Addition of David Tokofsky to its National Board of Advisors [0] Reportlinker Adds The Future of Cardiovascular Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis [0] Hospira to Acquire Orchid's Generic Injectable Pharmaceuticals Business [0] More about sex and relationships needed at gynecological visits

... (HealthDay News) -- It,s under your movie seat and glued ... relief may be in sight. This week, researchers say they,ll ... at the BA Festival of Science in York, England. , ... and sidewalks, and preliminary tests indicate that it degrades naturally ...

... KALAMAZOO, Mich., Sept. 14 Stryker,Corporation (NYSE: SYK ... investor conference: September 25, 2007 - 4:30 p.m. ... New York, New York A simultaneous webcast of ... http://www.stryker.com via the For Investors page. The,presentation ...

... Sept. 14 Mylan Laboratories Inc.,(NYSE: MYL ... Lacerca to the,position of Senior Vice President and ... from Bristol-Meyers Squibb where she was,Director of Compliance ... she was responsible for all compliance-related matters in ...

... Sept. 14 - The successful,implementation of electronic (e) ... $1.2 million per month according to a recent,news ... increased quality,demonstrated in Mississippi reinforces the importance in ... Association,(PCMA) said today., "The state of Mississippi ...

... difference between the two protective treatments , FRIDAY, Sept. 14 ... that a pill called dabigatran etexilate (DE) is just as ... of blood clots after total hip replacement surgery. , As ... the study included almost 3,500 hip replacement patients who received ...

... cancer survivor, General,Colin Powell is doing his part to ... prevention. In 2003, the former Secretary of State ... Since that time, General Powell has,contributed his time to ... sponsors Prostate Cancer Awareness Week (PCAW). "Early detection ...

Other Medicine News:Health News:Stryker to Present at Investor Conference 2 Health News:Mylan Announces Appointment of M. Fabiana Lacerca as Senior Vice President and Chief Compliance Officer 2 Health News:E-Prescribing Saving Mississippi Medicaid $1.2 Million Per Month 2 Health News:Pill Equals Injection in Preventing Clots After Hip Replacement 2 Health News:General Colin Powell Speaks Out for Prostate Cancer Prevention 2

Non-Stick Gum Something to Chew On Stryker to Present at Investor Conference Mylan Announces Appointment of M. Fabiana Lacerca as Senior Vice President and Chief Compliance Officer E-Prescribing Saving Mississippi Medicaid $1.2 Million Per Month Pill Equals Injection in Preventing Clots After Hip Replacement General Colin Powell Speaks Out for Prostate Cancer Prevention

... ADVIA Urinalysis WorkCell System - ... 90 tests per hour, with true ... integration of Clinitek Atlas and UF-100 ... highly regarded systems working together deliver ...

... one of the 3 major naturally occurring ... In terms of estrogenic activity, estriol is ... is produced almost exclusively during pregnancy, and ... normal human fetus. During pregnancy, the production ...

... Estrone Sulfate (E1S) is the most ... well as normal men [1,2]. Estrone Sulfate ... estrone, and has a longer half-life in ... levels generally parallel those of estrone and ...

Helmer's Horizon Series line of refrigerators are designed specifically for the cost conscious buyer. This line offers outstanding performance, quality, and the features you need to ensure the safety...

Medicine Products:

ADVIA Urinalysis WorkCell Unconjugated Estriol, Ultra-Sensitive RIA Test Estrone Sulfate, Ultra-Sensitive RIA Test Horizon Series™ HB245 Blood Bank Refrigerator

SCOLR Pharma, Inc. Reports Third Quarter 2008 Financi...( The Company also completed its previo...),Health